Novo Nordisk A/S (NVO) Study Shows Tresiba Efficacy for Diabetes
9/26/2013 7:41:45 AM
New data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) show that the majority of type 2 diabetes patients receiving the recently launched Tresiba (insulin degludec) plus metformin were able to maintain good glycemic control for 2.5 years. Specifically, 80.5 percent of those patients who were in good glycemic control after two years with Tresiba plus metformin maintained HbA1c below 7 percent when continuing treatment with Tresiba and metformin only, in a further 26-week add-on study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by